SAN MARCOS, Texas, Oct. 12 /PRNewswire/ -- Researchers at Texas State University-San Marcos have completed initial testing of a cancer chemotherapeutic and anti-retroviral compound with promising results.
Dhiraj Vattem, professor in the Department of Family and Consumer Sciences, and Reed Richardson, professor in the Department of Agriculture, supervised the tests in cooperation with Orizon Research. Results were announced at a University press conference.
The product, known as ALKA-V6, is a proprietary modified silicon-based compound developed by Orizon Research. The in-vitro evaluations will be followed by a second phase of testing for ALKA-V6 which will consist of end-point evaluations in in-vivo systems. Results from second-phase testing are expected within the next 12 months.
The anticancer studies revealed ALKA-V6:
The anti-retroviral studies revealed ALKA-V6:
The unique electrochemical and structural composition of ALKA-V6 indicates that it may provide an alternative basis for control of cancer cell growth and virus survival. However, this implication is based solely on in-vitro results and end-point in-vivo evaluations are imperative.
Orizon Research Institute of Odessa, Texas is the international distributor of ALKA V-6, which is currently being sold as a nutritional supplement on the company web site. The entire research study is also available on the Orizon Research web site at www.orizonresearch.com.
SOURCE Orizon Research Institute
|SOURCE Orizon Research Institute|
Copyright©2009 PR Newswire.
All rights reserved